ixlayer is a technology company.
ixlayer has raised $75.0M across 1 funding round.
ixlayer has raised $75.0M in total across 1 funding round.
ixlayer has raised $75.0M in total across 1 funding round.
ixlayer's investors include Andreessen Horowitz, AYANA Capital LLC, BDC Venture Capital, Bennu, Cota Capital, CRV, EQT Ventures, Flucas Ventures, Flybridge Capital Partners, Founder Collective, Franklin Templeton Investments, General Catalyst.
ixlayer is a San Francisco-based health technology company that provides a leading cloud-based platform for end-to-end direct-to-patient healthcare experiences, primarily serving biopharma organizations, health systems, clinical labs, and consumer companies.[1][2][5] The platform, called ixEngage, integrates services like remote lab testing, telehealth, prescription fulfillment, payments, and provider connections to simplify patient journeys, boost engagement, and improve health outcomes—such as increasing patient activation and diagnostic compliance above U.S. benchmarks.[2][3] It has powered over 1,100 nationwide programs and 4 million patient care journeys, with a team of 51-200 employees focused on operational efficiency and scalability.[2][5]
ixlayer solves key challenges in healthcare access by enabling earlier diagnoses, affordable testing, and seamless connections across the ecosystem, driving brand loyalty for clients while enhancing patient experiences through intuitive interfaces and white-labeled solutions.[1][2][3]
Founded in 2017 with a mission to enable remote lab testing, ixlayer has evolved into the world's most sought-after direct-to-patient platform.[1] Co-founder and CEO Pouria Sanae brings experience from Helix (leading 22 genomics product launches), Yahoo, Flickr, and his prior startups CMS and Cityblis.[1] Chief Product Officer David Yu contributes over 25 years in digital products across healthcare, media, fintech, and e-commerce.[1] Other key leaders include CTO Vahid Kowsari and Co-founder/VP Engineering Rohan Marr.[7]
The idea emerged from a need to connect industry players for accessible health testing, gaining early traction through partnerships and expansions into full patient journeys, including telehealth and Rx services amid the rise of virtual care.[1][4]
ixlayer rides the wave of direct-to-patient (DTP) healthcare and virtual care trends, accelerated by post-pandemic demand for remote diagnostics, telehealth, and personalized medicine.[1][4][8] Timing is ideal amid rising biopharma needs for patient engagement in clinical trials and chronic care, fueled by AI/ML for workflows, data interoperability challenges, and health equity pushes.[6][8] Market forces like regulatory support for DTP, cloud adoption, and precision health favor its model, enabling biopharma to launch programs faster while addressing access gaps in diagnostics and treatments.[3][5][7]
It influences the ecosystem by powering nationwide programs for leading players, fostering earlier interventions, and setting standards for integrated platforms that boost compliance and outcomes, as seen in expansions like dermatological care.[2][8]
ixlayer is poised for accelerated growth by expanding its ixEngage platform into more therapeutic areas, leveraging AI for predictive patient insights, and deepening integrations amid booming digital health demand.[6][8] Trends like AI-driven personalization, regulatory tailwinds for virtual care, and biopharma's focus on patient-centricity will shape its path, potentially scaling to tens of millions of journeys. Its influence may evolve from enabler to category leader, transforming how biopharma delivers equitable, efficient care—building on its foundation as the go-to platform for direct-to-patient innovation.[1][2]
ixlayer has raised $75.0M across 1 funding round. Most recently, it raised $75.0M Series A in March 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2021 | $75.0M Series A | Andreessen Horowitz, AYANA Capital LLC, BDC Venture Capital, Bennu, Cota Capital, CRV, EQT Ventures, Flucas Ventures, Flybridge Capital Partners, Founder Collective, Franklin Templeton Investments, General Catalyst, Interlace Ventures, MBX Capital, Next47, Pear VC, PivotNorth Capital, Real Ventures, Sonder Capital, White Star Capital, Xfund, Anil Dharni, Gokul Rajaram, Jim Pallotta, Patrick S. Chung, Robert Ciardi, Scott Belsky, Warren Jenson |